Pharming Group NV
$ 17.80
0.68%
15 Apr - close price
- Market Cap 1,248,654,000 USD
- Current Price $ 17.80
- High / Low $ 18.41 / 17.56
- Stock P/E 442.00
- Book Value 0.42
- EPS 0.04
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.01 %
- 52 Week High 21.34
- 52 Week Low 8.05
About
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Analyst Target Price
$34.60
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-10-22 | 2025-07-31 | 2025-05-06 | 2025-03-12 | 2024-10-24 | 2024-08-01 | 2024-05-08 | 2024-03-14 | 2023-10-26 | 2023-08-03 | 2023-05-11 |
| Reported EPS | 0.07 | 0.1 | 0.01 | -0.022 | 0.005 | -0.0153 | -0.0177 | -0.1851 | -0.0406 | 0.005 | 0.01 | -0.17 |
| Estimated EPS | 0.0117 | -0.125 | -0.0125 | -0.025 | 0.0085 | -0.0025 | -0.002 | 0.007 | 0.0045 | 0.01 | 0.01 | -0.17 |
| Surprise | 0.0583 | 0.225 | 0.0225 | 0.003 | -0.0035 | -0.0128 | -0.0157 | -0.1921 | -0.0451 | -0.005 | 0 | 0 |
| Surprise Percentage | 498.2906% | 180% | 180% | 12% | -41.1765% | -512% | -785% | -2744.2857% | -1002.2222% | -50% | 0% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAR
2026-04-13 20:39:07
Pharming Group N.V. (PHAR) presented at the 25th Annual Needham Virtual Healthcare Conference. The company published a slide deck in conjunction with this event. The article was written by SA Transcripts, which is responsible for developing transcript-related projects and publishing thousands of quarterly earnings calls.
2026-04-13 16:10:08
The Portnoy Law Firm has announced an investigation into potential securities fraud allegations against Pharming Group N.V. following a significant drop in its American Depositary Receipt (ADR) price. This decline was triggered by a U.S. FDA Complete Response Letter regarding the expanded use of its drug Joenja® (leniolisib), citing concerns about dosing for pediatric patients and analytical methods. The firm is inviting investors to discuss their legal rights and potential class action.
2026-04-10 19:41:08
Canaccord Genuity has initiated coverage of Pharming Group NV (PHAR) with a "buy" recommendation. This suggests a positive outlook from the firm regarding the company's stock performance.
2026-04-09 19:10:08
Pharming Group N.V. will report its preliminary unaudited financial results for the third quarter of 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors at 13:30 CET/07:30 am ET on the same day. The company is a global biopharmaceutical firm focused on rare, debilitating, and life-threatening diseases.
2026-04-09 04:39:06
Pharming Group N.V. will report its preliminary first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on the same day, requiring advance registration to participate in the conference call or live webcast. Pharming is a global biopharmaceutical company focusing on rare, debilitating, and life-threatening diseases, with headquarters in the Netherlands.
2026-04-08 19:10:08
Pharming Group N.V. announced its participation in two investor conferences in April 2026: the 25th Annual Needham Virtual Healthcare Conference and the Van Lanschot Kempen Life Sciences Conference 2026. Management, including CEO Fabrice Chouraqui and CMO Anurag Relan, will present at the Needham conference. Investors can contact Pharming's Investor Relations for more information or to schedule meetings.
